BCR-ABL1 expression in quiescent CML-LSCs, but not its activity, allows for the recruitment and the activation of other oncogenes, such as JAK2, and it enhances β-catenin activity. Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.